Találati lista | Tudóstér

001-es BibID:	BIBFORM047606
035-os BibID:	PMID:23590152
Első szerző:	Juhász Béla (kísérletes farmakológus)
Cím:	Cardioprotective Effects of Sour Cherry Seed Extract (SCSE) on the Hypercholesterolemic Rabbit Heart / Bela Juhasz, Attila Kertész, Jozsef Balla, Gyorgy Balla, Zoltán Szabo, Mariann Bombicz, Daniel Priksz, Rudolf Gesztelyi, Balazs Varga, David D. Haines, Arpad Tosaki
Dátum:	2013
ISSN:	1381-6128
Megjegyzések:	Hypothesis. The present study evaluates the hypothesis that sour cherry seed extract (SCSE) protects against cardiovascular disease and inflammation in hypercholesterolemic rabbits, and that this protection correlates with SCSE-induced activity of heme oxygenase-1 (HO-1), a cytoprotective enzyme contributing to oxidative stress responses. Methods: 18 New Zealand white rabbits were divided into three groups receiving: I. cholesterol-free rabbit chow; II. chow containing 2% cholesterol; or III. 2% cholesterol plus SCSE for 16 weeks. Heart functions were monitored by echocardiography 0, 4, and 16 weeks after the initiation of cholesterol-supplemented feeding. At the 16-week time-point, isolated hearts were subjected to ischemia-reperfusion (I/R), followed by measurement of heart rate (HR), aortic flow (AF), coronary flow (CF), aortic pressure (AoP), and left ventricular developed pressure (LVDP). Myocardial infarct size was determined using triphenyl tetrazolium chloride (TTC). Quantification of fatty streaks was assessed using Sudan-III staining. Western blot analysis was used to determine the content of cytochrome c oxidase III (COX III), vascular endothelial growth factor (VEGF), and HO-1 in the myocardium. Results: Relative to cholesterol-treated animals not receiving SCSE, SCSE-treated animals exhibited significantly improved cardiac function and improved peak early diastolic velocity to peak atrial velocity ratio (E'/A'), along with decreased the atherosclerotic plaque formation and infarct size. Increased HO-1 and COX III protein expression and COX activity were also noted in hearts from SCSE-treated rabbits. Conclusions: This study demonstrates SCSE cardioprotective effects on hypercholesterolemic hearts. Correlation of these outcomes with HO-1 expression suggests that the effect may be mediated by activity of this enzyme. However, definitive proof of HO-1 dependence requires further investigation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Current Pharmaceutical Design. - 19 : 39 (2013), p. 6896-6905. -
További szerzők:	Kertész Attila Béla (1973-) (kardiológus) Balla József (1959-) (belgyógyász, nephrológus) Balla György (1953-) (csecsemő és gyermekgyógyász, neonatológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Bombicz Mariann (1987-) (gyógyszerész) Priksz Dániel (1989-) (farmakológus) Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Varga Balázs (1984-) (kísérletes farmakológus) Haines, David Donald (1981-) (gyógyszerész) Tósaki Árpád (1958-) (kísérletes farmakológus, gyógyszerész)
Pályázati támogatás:	TÁMOP-4.2.2.A-11/1/KONV-2012-0045 TÁMOP MTA-DE MTA-DE Vascularis Biológia, Thrombosis- Haemostasis Kutatócsoport 11003 TÁMOP-4.2.2/B-10/1-2010-0024 TÁMOP Gyógyszerészeti Tudományok Doktori Iskola TÁMOP-4.2.1/B-09/1/KONV-2010-0007 TÁMOP Kardiovaszkuláris megbetegedések génterápiás befolyásolása TÁMOP-4.2.4.A/2-11-1-2012-0001 TÁMOP
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM056739
Első szerző:	Szentmiklósi József András (farmakológus, klinikai laboratóriumi szakorvos)
Cím:	The janus face of adenosine : antiarrhythmic and proarrhythmic actions / A. József Szentmiklósi, Zoltán Galajda, Ágnes Cseppentő, Rudolf Gesztelyi, Zsolt Susán, Bence Hegyi, Péter P. Nánási
Dátum:	2015
ISSN:	1381-6128
Megjegyzések:	Adenosine is a ubiquitous, endogenous purine involved in a variety of physiological and pathophysiological regulatory mechanisms. Adenosine has been proposed as an endogenous antiarrhythmic substance to prevent hypoxia/ischemia-induced arrhythmias. Adenosine (and its precursor, ATP) has been used in the therapy of various cardiac arrhythmias over the past six decades. Its primary indication is treatment of paroxysmal supraventricular tachycardia, but it can be effective in other forms of supraventricular and ventricular arrhythmias, like sinus node reentry based tachycardia, triggered atrial tachycardia, atrioventricular nodal reentry tachycardia, or ventricular tachycardia based on a cAMP-mediated triggered activity. The main advantage is the rapid onset and the short half life (1- 10 sec). Adenosine exerts its antiarrhythmic actions by activation of A1 adenosine receptors located in the sinoatrial and atrioventricular nodes, as well as in activated ventricular myocardium. However, adenosine can also elicit A2A, A2B and A3 adenosine receptor-mediated global side reactions (flushing, dyspnea, chest discomfort), but it may display also proarrhythmic actions mediated by primarily A1 adenosine receptors (e.g. bradyarrhythmia or atrial fibrillation). To avoid the non-specific global adverse reactions, A1 adenosine receptor- selective full agonists (tecadenoson, selodenoson, trabodenoson) have been developed, which agents are currently under clinical trial. During long-term administration with orthosteric agonists, adenosine receptors can be internalized and desensitized. To avoid desensitization, proarrhythmic actions, or global adverse reactions, partial A1 adenosine receptor agonists, like CVT-2759, were developed. In addition, the pharmacologically "silent" site- and event specific adenosinergic drugs, such as adenosine regulating agents and allosteric modulators, might provide attractive opportunity to increase the effectiveness of beneficial actions of adenosine and avoid the adverse reactions.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Adenosinergic drugs antiarrhythmic action proarrhythmic effect adenosine A1 receptor activators partial A1 adenosine receptor agonists adenosine regulators allosteric receptor modulators drug development
Megjelenés:	Current Pharmaceutical Design. - 21 : 8 (2015), p. 965-976. -
További szerzők:	Galajda Zoltán (1962-) (szívsebész, érsebész) Cseppentő Ágnes (1953-) (orvos) Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Susán Zsolt (1983-) (sebész) Hegyi Bence (1987-) (élettanász) Nánási Péter Pál (1956-) (élettanász)
Pályázati támogatás:	TÁMOP-4.2.2.A-11/1/KONV-2012-0045 TÁMOP Sebészet Kutatócsoport
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: